RXi Pharmaceuticals (RXII +16%) pops after the firm gives a positive update on its phase 3...

|By:, SA News Editor

RXi Pharmaceuticals (RXII +16%) pops after the firm gives a positive update on its phase 3 clinical trial of NeuVax, a cancer immunotherapy targeted for breast cancer patients not eligible for other treatment.